A new era of DNA-based drugs for precision medicine.
Biogenera develops a new generation of PNA-based anti-gene oligonucleotide drugs (Ag-PNA) to treat diseases that are currently incurable. Thanks to an innovative approach that acts directly on the individual genes altered at the root of the diseases, we aim to save the lives of those facing aggressive cancers and other serious conditions.
A new era of DNA-based drugs for precision medicine.
Biogenera develops a new generation of PNA-based anti-gene oligonucleotide drugs (Ag-PNA) to treat diseases that are currently incurable. Thanks to an innovative approach that acts directly on the individual genes altered at the root of the diseases, we aim to save the lives of those facing aggressive cancers and other serious conditions.
DNA-based drugs for precision medicine
BIOGENERA SpA is a company operating in the pharmaceutical biotechnology sector, specializing in the research and development of new personalized DNA-based biotechnological drugs for the treatment of serious diseases.
Founded in 2008 and based in Bologna, BIOGENERA SpA is an innovative small-to-medium enterprise (innovative SME), supported by a multidisciplinary team of researchers and numerous partnerships with universities (particularly the University of Bologna) and companies in the pharmaceutical sector.
01
A New Approach
to Treatment
Our drugs silence the individual altered genes responsible for diseases by acting directly on the DNA.
02
MyGenera™:
Revolutionary Technology
The patented platform MyGenera™ rapidly identifies PNA-based anti-gene oligonucleotides (Ag-PNA) capable of selectively targeting altered genes.
03
BGA002: Therapy for Pediatric Tumors
BGA002 works by silencing the MYCN gene, the main driver of the most aggressive childhood cancers, with a precise and safe action.
04
Pipeline: The Future of Gene Therapy
In addition to BGA002, we are working on new gene therapies for resistant tumors and rare diseases, expanding treatment possibilities.
05
Partnerships and Collaborations
Biogenera collaborates with pharmaceutical companies and investors to accelerate drug development and bring innovation to patients.
English 
Italian